Core Viewpoint - The announcement details the completion of a share reduction plan by a significant shareholder of Tuoxin Pharmaceutical, indicating a decrease in the shareholding percentage of the controlling shareholder and its concerted parties, but clarifying that this will not impact the company's governance structure or control [1]. Group 1: Share Reduction Details - The concerted party, Yiwos Trading Co., Ltd., reduced its holdings by a total of 3,122,086 shares, representing 2.47% of the company's total share capital [1]. - The reduction occurred through two methods: 1,265,400 shares were sold via centralized bidding at an average price of 30.93 yuan per share from March 14 to May 19, and 1,856,686 shares were sold through block trading at an average price of 27.03 yuan per share from April 1 to June 6 [1][2]. - The overall average selling price for the shares reduced was 28.61 yuan per share, resulting in a total reduction amount of approximately 89.32 million yuan [1]. Group 2: Company Background and Financials - Tuoxin Pharmaceutical was listed on the Shenzhen Stock Exchange's Growth Enterprise Market on October 27, 2021, with an initial public offering of 31.5 million shares at a price of 19.11 yuan per share [2]. - The total funds raised from the initial public offering amounted to 602 million yuan, with a net amount of 543 million yuan after deducting issuance costs, exceeding the original plan by 148 million yuan [3]. - The funds raised are intended for projects including the construction of nucleoside series specialty raw materials and pharmaceutical intermediates, the establishment of the Tuoxin Pharmaceutical Research Institute, and to supplement working capital [3].
拓新药业实控人方近3个月减持312万股 套现8932万元